Bionano Genomics (NASDAQ:BNGO) Shares to Reverse Split on Monday, January 27th

Shares of Bionano Genomics, Inc. (NASDAQ:BNGO) are going to reverse split before the market opens on Monday, January 27th. The 1-60 reverse split was announced on Wednesday, January 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 24th.

Bionano Genomics Stock Down 28.7 %

Bionano Genomics stock traded down $0.05 during mid-day trading on Thursday, reaching $0.13. 31,894,418 shares of the company’s stock were exchanged, compared to its average volume of 19,639,521. The company has a market cap of $15.47 million, a P/E ratio of -0.06 and a beta of 2.22. Bionano Genomics has a twelve month low of $0.13 and a twelve month high of $1.36. The company has a quick ratio of 0.99, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. The company has a fifty day moving average of $0.23 and a 200-day moving average of $0.38.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH lowered shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a report on Friday, November 15th.

Institutional Trading of Bionano Genomics

Institutional investors have recently bought and sold shares of the business. Armistice Capital LLC acquired a new stake in Bionano Genomics during the 2nd quarter worth $1,138,000. Geode Capital Management LLC grew its stake in Bionano Genomics by 47.3% during the 3rd quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock worth $401,000 after buying an additional 283,639 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Bionano Genomics during the third quarter worth approximately $46,000. Finally, Carret Asset Management LLC lifted its stake in Bionano Genomics by 89.0% in the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after buying an additional 40,055 shares during the last quarter. 11.35% of the stock is owned by hedge funds and other institutional investors.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.